The Celljuvant Study: A Phase 3 Immunogenicity and Safety Study of aQIVc Vaccine in Adults Aged 50 Years and Older

About the trial

Sponsor

Seqirus

Tested

Investigational aQIVc (biological), licensed QIVr (biological), licensed aQIV (biological)

Dates

Started 2023-11-03; completion 2025-01-30

Results posted

Not yet

This is a Phase 3, randomized, parallel-group, comparator-controlled, observer-blind, multicenter study of immunogenicity and safety in approximately 7700 male and female adults aged 50 years and older (approximately equally split between two age groups: 50-64 years; 65 years and older), who are healthy or have stable comorbidities that increase their risk of complications from influenza infection. Three lots of aQIVc will be evaluated for consistency and pooled for the comparison with the 2 control vaccines. Subjects will be randomly assigned to receive 1 of 3 lots of aQIVc, QIVr, or aQIV in a 1:1:1:2:2 ratio (for a 3:2:2 ratio for aQIVc, QIVr, and aQIV). The study will have a treatment …

From ClinicalTrials.gov, last updated 2025-04-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Seqirus USA Inc reported $2.1M in research payments for this study in 2025 (2,587 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.